Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like AI identifies new high-risk subtype in endometrial cancer June 28, 2024 Older brains adapt to recognize music by reconfiguring neural activity September 11, 2024 Study reveals the effects of wearing cosmetic foundation on the skin during aerobic exercise March 6, 2024
Study reveals the effects of wearing cosmetic foundation on the skin during aerobic exercise March 6, 2024